SPOT-MAS Lung: AI-Powered Blood Test Brings New Hope to High-Risk Non-Smokers in Asia
SINGAPORE, May 20, 2025 /PRNewswire/ -- In a bold step toward equitable cancer care, Gene Solutions introduces SPOT-MAS Lung, a next-generation blood-based test powered by artificial intelligence (AI) and multi-omics analysis. Designed with lung-specific features, SPOT-MAS Lung may offer a promising approach for earlier detection in Asia—especially among asymptomatic individuals who are often missed by traditional screening, or patients with symptoms but inconclusive imaging results.
Why does Lung Cancer Detection Matters in Asia lung cancer detection?
Asia bears the highest disease burden of lung cancer, accounting for 62% of global lung cancer deaths (1). Alarmingly, nearly 50% of patients in the region are diagnosed at the metastatic stage, when symptoms appear, and curative treatment is often no longer possible (2). When detected early, however, the prognosis improves dramatically — with 5-year survival rates increasing more than fourfold (3). Therefore, early screening plays a critical role in improving patient outcomes.
A Missed Window: Asymptomatic Patients Outside the Guidelines
Although smoking-based screening has been effective for certain populations, complementary approaches could help broaden detection to include other at-risk groups (4). Lung cancer in never-smokers (LCINS) was the fifth leading cause of cancer death globally (5). In Asia, 61.9% to 72.9% of lung cancer cases may be missed under current screening frameworks, with never-smokers disproportionately affected (6, 7). Notably, among women with lung cancer, 84.5% did not meet screening eligibility (6), leaving many asymptomatic individuals undetected until treatment is no longer curative.
Each Asian country defines the high-risk population for lung cancer screening differently. However, in most cases, "high-risk" is commonly understood as individuals with a smoking history exceeding 30 pack-years (8). Only a few countries—such as China—include additional criteria, such as living or working in the same room with smokers for ≥20 years (9). Other potentially high-risk groups remain unaddressed or are not included in official screening recommendations.
Unclear Pathways for Symptomatic Cases
Despite its role in standardizing low-dose CT (LDCT) screening for lung cancer, the Lung-RADS system has notable limitations that can complicate clinical decision-making. One major challenge is the lack of guidance for ambiguous findings—such as lung nodules that become denser without increasing in size. These scenarios are not clearly addressed in current Lung-RADS criteria, leaving clinicians uncertain about the next steps (10). As a result, patients may face either unnecessary follow-up procedures or delays in treatment.
SPOT-MAS is a blood-based test developed by Gene Solutions to detect cancer by analyzing multiple features of circulating tumor DNA (ctDNA) shed by tumor cells. It was previously validated as a multi-cancer early detection (MCED) assay through a longitudinal study of 9,024 healthy individuals (11). While the ability to screen for multiple cancers—including lung cancer—in a single blood draw is a promising milestone, a major challenge remains making such advanced testing affordable at scale.
To address this challenge, SPOT-MAS Lung test integrates a multi-omics tumor ATLAS with AI models trained on Asian population data to reduce the cost while maintaining high performance with 90% sensitivity and 92% specificity (12). This test applies analyzing a comprehensive set of biological signals including fragmentomics, nucleosome positioning, copy number alterations (CNAs), and 4-mer end motifs. Outstanding results from analytical evaluations were published in Future Oncology and presented at the European Lung Cancer Congress (ESMO Lung 2025). Importantly, the SPOT-MAS Lung study demonstrated no significant difference in classification performance between smokers and non-smokers (12), supporting its utility for early detection in high-risk groups—particularly in Asia, where never-smoker lung cancer is disproportionately common.
For asymptomatic individuals at high risk, such as never-smokers or women, SPOT-MAS Lung's non-invasive, blood-based approach is a hope to make early detection more accessible. Meanwhile, for patients with symptoms but inconclusive imaging, SPOT-MAS Lung might provide a way to monitor molecular changes over time, offering clinicians additional insights to support timely and informed decisions. By complementing current screening programs, SPOT-MAS Lung helps ensure that no one is left behind on the path to early diagnosis. Another multicenter validation study is planned in Singapore to prospectively assess the performance of the SPOT-MAS Lung test in both screening and diagnostic populations.
Prof. Dr. Anand Sachithanandan, Founding President of Lung Cancer Network Malaysia (LCNM), emphasized the value of innovation in early detection:
"The technology has immense potential to refine and augment existing screening, including addressing the unmet need to diagnose lung cancer earlier in high-risk non-smokers — a cohort neglected by traditional screening criteria."
Community-Based Screening to Bridge the Gap
To translate clinical innovation into public impact, Gene Solutions partnered with 365 Cancer Prevention Society (365CPS) and Bethesda Medical Centre to bring SPOT-MAS Lung into the community. As part of a public health initiative in Singapore, the collaboration offered 120 free tests through an outreach screening event designed to increase awareness and expand access to early detection.
"Bethesda is proud to collaborate with Gene Solutions and 365CPS in this meaningful initiative," said a Bethesda spokesperson. "Early detection is crucial in cancer prevention and management, and we are dedicated to supporting community-based efforts that promote health equity."
Ultimately, regardless of the method, raising awareness around detection quality—especially for high-risk individuals—is essential. Only through earlier, more inclusive detection can we begin to close the critical gaps in lung cancer outcomes. This aligns with Gene Solutions' core mission: to deliver accessible, precision-based cancer screening that meets the needs of real people, in real communities, across Asia.
Gene Solutions, a multinational biotech company in Asia, is leading the way in leveraging advanced AI and ctDNA technologies for innovative cancer detection solutions. The company partners with over 4,500 hospitals and clinics across Southeast Asia and boasts a team of approximately 250 biology experts and technicians out of a total of 700 employees.
Gene Solutions has published more than 50 peer-reviewed publications and conducted over 50 multi-center studies across the region. The company, recognized for its proprietary research and CAP-accredited laboratories in Singapore and Vietnam, combines multi-dimensional genomics with AI-driven approaches to transform cancer care.
(2) Lam, D. C.-L.; Liam, C.-K.; Andarini, S.; Park, S.; Tan, D. S. W.; Singh, N.; Jang, S. H.; Vardhanabhuti, V.; Ramos, A. B.; Nakayama, T.; Nhung, N. V.; Ashizawa, K.; Chang, Y.-C.; Tscheikuna, J.; Van, C. C.; Chan, W. Y.; Lai, Y.-H.; Yang, P.-C. Lung Cancer Screening in Asia: An Expert Consensus Report. Journal of Thoracic Oncology 2023, 18 (10), 1303–1322.
(3) Statistics adapted from the American Cancer Society's (ACS) publication, Cancer Facts & Figures 2022 and Cancer Facts & Figures 2021; the ACS website; and the International Agency for Cancer Research website.
(4) Infante, M. V.; Cardillo, G. Lung Cancer Screening in Never-Smokers: Facts and Remaining Issues. Eur Respir J 2020, 56 (5), 2002949.
(5) Kim, R. Y. Insights Into Opportunistic Lung Cancer Screening for Individuals Who Have Never Smoked. JAMA Netw Open 2025, 8 (1), e2454009.
(6) Loh, C. H.; Koh, P. W.; Ang, D. J. M.; Lee, W. C.; Chew, W. M.; Koh, J. M. K. Characteristics of Singapore Lung Cancer Patients Who Miss out on Lung Cancer Screening Recommendations. Singapore Medical Journal 2024, 65 (5), 279–287.
(7) Kakinuma, R.; Muramatsu, Y.; Asamura, H.; Watanabe, S.; Kusumoto, M.; Tsuchida, T.; Kaneko, M.; Tsuta, K.; Maeshima, A. M.; Ishii, G.; Nagai, K.; Yamaji, T.; Matsuda, T.; Moriyama, N. Low-Dose CT Lung Cancer Screening in Never-Smokers and Smokers: Results of an Eight-Year Observational Study. Transl Lung Cancer Res 2020, 9 (1), 10–22.
(8) Pinsky PF. Lung cancer screening with low-dose CT: a world-wide view. Transl Lung Cancer Res. 2018 Jun;7(3):234–242. doi: 10.21037/ tlcr.2018.05.12
(9) National Health Commission of the People's Republic of China. (2024, August 27). Notice of the General Office on the issuance of the Lung Cancer Screening, Early Diagnosis and Treatment Program (2024 Edition). Department of Medical Emergency.
(10) Martin, M. D.; Kanne, J. P.; Broderick, L. S.; Kazerooni, E. A.; Meyer, C. A. Lung-RADS: Pushing the Limits. RadioGraphics 2017, 37 (7), 1975–1993.
(11) Nguyen, et. al. (2025) Prospective validation study: a non-invasive circulating tumor DNA-based assay for
(12) Nguyen, V. T. C., et al. (2025). Cost-effective shallow genome-wide sequencing for profiling plasma cfDNA signatures to enhance lung cancer detection. Future Oncology, 1–12.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
2 days ago
- Korea Herald
UTM RANKED 153RD IN QSWUR 2026: INNOVATING SUSTAINABLE SOLUTIONS FOR A BETTER FUTURE
JOHOR BAHRU, Malaysia, June 20, 2025 /PRNewswire/ -- Universiti Teknologi Malaysia (UTM) has made a significant leap in the QS World University Rankings 2026, climbing to 153rd position globally, placing it in the top 10.2% of over 1,500 evaluated institutions. UTM's improved standing in the QS World University Rankings is the result of strategic progress across several key dimensions, including a remarkable climb of 112 places in International Research Network (now ranked 3rd in Malaysia), a 45-place rise in Citations per Faculty (also 3rd in Malaysia), an 8-place improvement in Academic Reputation, a 28-place gain in Faculty-Student Ratio, and a strong showing in International Student Diversity, where UTM is ranked 132nd globally with students representing 85 nationalities. While the achievement reflects the university's academic and research strength, UTM is equally focused on a broader mission: creating a better world through sustainability, values, and the humanities. "UTM's mission is clear — to nurture global talents and to enrich lives through knowledge and innovative technologies. In this context, rankings serve as an important measurement tool to attract top talents. However, beyond rankings, we believe our UTM community is driven by values and wisdom to contribute to a better world," said Professor Dr Mohd Shafry Mohd Rahim, Vice Chancellor of UTM. This ethos is anchored in UTM's strategic tagline: Innovating Sustainable Solutions —a bold commitment to address global and local challenges by embedding sustainability, human values, and inclusive development into all aspects of the university's teaching, research, and community engagement. More Than a Ranking: A Mission for Humanity "Being recognised among the world's top universities is a proud milestone for our community," said Professor Shafry. "But our mission goes beyond rankings. It is about nurturing global talents, enriching lives, and driving sustainable change grounded in values and wisdom. At the heart of this mission is our commitment to humanising and democratising knowledge—ensuring that our innovations in engineering, science and technology serve people, communities, and the greater good." This mission has shaped UTM into a university that not only produces top-tier engineers, scientists, and innovators, but also well-rounded graduates who understand their roles as global citizens. In every research lab, classroom, and community partnership, UTM promotes integrity, empathy, cultural appreciation, and respect for future generations. UTM's focus on sustainability and humanities is not symbolic but strategic. In 2024, its Faculty of Artificial Intelligence was launched during the Malaysia Artificial Intelligence Nexus programme. The faculty was positioned as Malaysia's inaugural AI-focused faculty emphasising human-centred values and ethics. Designed to foreground values of humanity, the faculty's goal is to produce graduates who can apply AI ethically, ensuring fairness, transparency, and accountability in technology development. UTM also leads Malaysia's Artificial Intelligence Consortium (MAIC), bridging academia, public and private sectors to coordinate AI solutions across fields like healthcare, climate, and finance. Sustainability: The University's DNA The UTM Green Campus initiative remains one of the most impactful in the region, integrating smart energy systems, sustainable transportation, and eco-friendly infrastructure into everyday campus life. Guided by the UTM Living Labs framework, the Sustainability Blueprint, and environmental, social and governance (ESG) policies, this initiative reflects the university's commitment to environmental responsibility and long-term climate action. UTM's research ecosystem supports this vision by addressing global challenges such as water and food security, low-carbon development, and urban resilience. The Centre for Environmental Sustainability and Water Security and the Low Carbon Asia Research Centre collaborate with government and industry to deliver science-based, people-focused solutions. UTM is also home to three Higher Institution Centres of Excellence: the Advanced Membrane Technology Research Centre, known for membrane innovations in sustainable industries; the Institute of Noise and Vibration, focused on acoustical engineering; and the Wireless Communication Centre, a leader in radio frequency and wireless research. The Institute for Sustainable Transport further strengthens UTM's role in advancing green mobility and smart urban development. Building Global Bridges for Shared Futures UTM's global engagement continues to expand, with partnerships across ASEAN, Europe, the Middle East, and Africa. Under frameworks like Erasmus+ CBHE, Horizon Europe, and the Asia Technological University Network, UTM is co-developing initiatives on climate education, social innovation, and equitable digital futures. Through the Office of Strategy and Global Eminence, UTM is aligning its institutional goals with the United Nations Sustainable Development Goals (SDGs), particularly in areas of clean energy, education, reduced inequalities, and responsible consumption. "Being ranked #153rd in the world is a significant recognition. But what we truly celebrate is our university's evolution into a transformative force for good," said Associate Professor Dr. Abdul Rashid Husain, Acting Associate Vice Chancellor, Office of Strategy and Global Eminence. "UTM is all about values, humanities, and sustainability. This is our DNA. This is our promise." About Universiti Teknologi Malaysia (UTM) Universiti Teknologi Malaysia (UTM) is a research-intensive public university specialising in engineering, science, and technology, with a growing international profile in sustainability, innovation, and the humanities. Established in 1904 and located in Johor Bahru and Kuala Lumpur, UTM is dedicated to producing global talents, impactful research, and meaningful partnerships that contribute to a more just and sustainable world.
Korea Herald
2 days ago
- Korea Herald
Gene Solutions Strengthens China Footprint with Strategic Partnerships in Precision Oncology
BEIJING, June 20, 2025 /PRNewswire/ -- Gene Solutions announces the signing of two strategic Memoranda of Understanding (MOUs) with ZaoDx and Xiong'an MagicBiotech Co., Ltd. These partnerships mark a focused expansion of Gene Solutions' precision oncology efforts into the Chinese market through collaborative technology introduction, research exploration, and localized deployment of its innovative cancer testing platforms. Together, the partnerships reinforce Gene Solutions' long-term commitment to supporting China's healthcare innovation ecosystem with advanced, clinically validated tools for early cancer detection and monitoring. Enabling Early Detection Through Ecosystem Engagement with ZaoDx Gene Solutions and ZaoDx have formed a strategic business alliance to jointly explore the introduction, promotion, and responsible commercialization of advanced early cancer screening technologies in China. This partnership will focus on: CEO of ZaoDx Dr. Chen Zanquan stated: "Cancer is a challenge faced globally, and early detection is crucial for cure. ZAODX is pleased to collaborate with Gene Solutions to advance the conversion and accessibility of innovative cancer screening and diagnosis technologies. I believe our joint efforts will bring tangible benefits to millions of families." "Our collaboration with ZaoDx reflects a shared commitment to bringing global innovation into meaningful local impact," said Jiang Hao, Business Development Manager at Gene Solutions. "By working alongside respected research-driven partners, we can responsibly introduce early detection technology to more patients and providers across the country." Advancing Research Collaboration in Northern China alongside MagicBiotech Gene Solutions and Xiong'an MagicBiotech have signed an MOU to jointly explore the introduction and academic evaluation of next-generation sequencing (NGS)–based oncology technologies across northern China. The collaboration will center on: "Our partnership with MagicBiotech is a cornerstone for advancing precision oncology in China," said Ida Deleskog Lindstrom, Global Medical Affairs Director at Gene Solutions. "By fostering collaborative research and leveraging local expertise, we aim to validate and scale our technologies to meet the region's clinical and scientific needs." Driving Localized Innovation Through Strategic Collaboration These dual partnerships represent a calibrated approach by Gene Solutions to support the introduction and validation of advanced oncology diagnostics in China. Both collaborations are built on mutual strengths—balancing scientific rigor, ethical commercialization, and long-term research-driven engagement. Project-specific initiatives under each MOU will be rolled out progressively in alignment with local regulations and institutional priorities. About ZaoDx ZAODX Early Screening Network is a globally leading platform dedicated to the early detection of diseases, with a core mission to drive the transformation of global healthcare systems from treatment-centric models to a proactive, health-centered paradigm. Guided by the widely recognized principle that "prevention is the most cost-effective and impactful health strategy," ZAODX advocates the global adoption of early screening, early diagnosis, and early treatment — while also drawing inspiration from Traditional Chinese Medicine's wisdom of "treating disease before it occurs." As a truly international and multidisciplinary team, ZAODX brings together key stakeholders across the global healthcare ecosystem — including scientists, entrepreneurs, investors, policymakers, healthcare providers, and public health experts — united by the mission to make health screening accessible and equitable for all. The network has established strategic partnerships with over 1,000 top-tier medical institutions, academic organizations, professional societies, independent laboratories, and healthcare innovators to foster cross-border academic exchange, scientific collaboration, technology translation, industry synergy, and public health education. Committed to global public health goals, ZAODX actively supports initiatives led by the World Health Organization and national health authorities. Through collaborative efforts, ZAODX is building an innovative and inclusive early screening ecosystem — empowering the global fight for earlier prevention, better outcomes, and healthier populations worldwide. About Xiong'An MagicBiotech Xiong'An MagicBiotech is a biotechnology company in Xiongan New Area focusing on "in vitro diagnostic reagents + testing services + artificial intelligence". MagicBiotech is mainly engaged in independent research and development, production and sales of in vitro diagnostic kits for genetic testing. By using multi-omics medical examination data and bioinformatics AI artificial intelligence technology, it provides in vitro diagnostic reagents and medical testing services to medical institutions and patients; in the scientific research and technology service sector, MagicBiotech has always adhered to the concept of innovation-driven, continued to increase R&D investment, and made every effort to build a complete and advanced technology platform system. The system deeply covers cutting-edge fields such as genomics, proteomics, metabolomics, microbiome, and single-cell multi-omics. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific.
Korea Herald
2 days ago
- Korea Herald
New Global Aesthetics Report: A Shift Towards Facial Surgery Globally as Eyelid Ranks Top Procedure
Aesthetic Procedures Close to 38 Million in 2024. MOUNT ROYAL, N.J., June 20, 2025 /PRNewswire/ -- The International Society of Aesthetic Plastic Surgery (ISAPS) released the results of its annual Global Survey on Aesthetic/Cosmetic Procedures at the ISAPS Olympiad World Congress in Singapore, showing more than 17.4 million procedures performed by plastic surgeons and 20.5 non-surgical procedures. Over the last four years, the overall increase is 42.5%. Eyelid surgery, for the first time, was the most common surgical procedure in 2024, replacing liposuction, with 2.1 million, followed by liposuction, breast augmentation, scar revision, and rhinoplasty. The most popular non-surgical procedures were botulinum toxin, hyaluronic acid (filler), hair removal, non-surgical skin tightening, and chemical peels. Most face and head procedures showed growth from the previous year, with more than 7.4 million procedures and a 4.3% increase. Top procedures were eyelid surgery with more than 2.1 million and a 13.4% increase, rhinoplasty with 1 million procedures and a 10% decrease, and fat grafting – face 0.9 million and a 19.2% increase. There were 3.9 million breast procedures (-14.1%) and 6 million body and extremities procedures (-14.8%). Liposuction was still the most common surgical procedure for women, followed by eyelid surgery and breast augmentation. Eyelid surgery was again the most popular surgical procedure among men, followed by gynecomastia and scar revision. Most breast augmentations (54% of the total), rhinoplasties (60.1%), and external genital surgery (48.4%) took place on 18–34-year-olds, whereas botulinum toxin injectables were most popular among those aged 35–50 (47.0% of the total). Liposuction and non-surgical fat reduction were distributed quite evenly among both age groups. Botulinum toxin remained the most common non-surgical procedure for both men and women and among all age groups, with 7.8 million procedures performed by plastic surgeons worldwide. In second place, hyaluronic acid procedures increased by 5.2% to 7.8 million. Commenting on the global results, Dr. Amin Kalaaji, Chair of the ISAPS Global Survey Committee and plastic surgeon in Norway, said, "Our report now includes data on 'Mommy Makeover' and other combined procedures, scar revision, hand rejuvenation with fat grafting, buccal fat removal, inverted nipple correction, dimple creation, and other outer genital surgery." Once again, the US performed the most procedures with over 6.1 million, followed by Brazil with 3.1 million (which is first in surgical procedures), and Japan.
